Price target
5.970.000.00%
The 5 analysts offering 1 year price forecasts for AX9 have a max estimate of — and a min estimate of —.
Analyst rating
Based on 5 analysts giving stock ratings to AX9 in the past 3 months.
EPS
Reported
Estimate
Reported
Estimate
Surprise
Revenue
Reported
Estimate
Reported
Estimate
Surprise
This info isn't a recommendation for what you should personally do, so please don't take the data as investment advice. As with any trade, always look first, then leap. Read more in the Terms of Use.
Frequently Asked Questions
AX9 EPS for the last quarter is CHF despite the estimation of −0.01 CHF. In the next quarter EPS is expected to reach −0.02 CHF. Track more of Akebia Therapeutics, Inc. financials and stay on top of what is up with the company.
In the next quarter Akebia Therapeutics, Inc. revenue is expected to reach 41.56 M CHF. Check out Akebia Therapeutics, Inc. revenue and earnings and make informed decisions.
According to analysts, AX9 price target is 5.97 CHF with a max estimate of 8.07 CHF and a min estimate of 4.84 CHF. Check if this forecast comes true in a year, meanwhile watch Akebia Therapeutics, Inc. stock price chart and keep track of the current situation with AX9 news and stock market news.
We've gathered opinions of 5 analysts rating AX9 stock in the past 3 months. Most of them backed up the strong buy trend, and after taking into account other opinions, the overall rating was calculated as strong buy. Note that it's not a trading advice — your own analysis is still required.